申请人:Novo Nordisk A/S
公开号:US05246935A1
公开(公告)日:1993-09-21
Piperazinyl derivatives of the general formula I ##STR1## wherein R.sup.1 represents substituted phenyl, 1- or 2-diazanaphthyl, azadiazanaphtyl or diazanaphtyl groups; n is 1, 2, 3 or 4; X is --O-- or ##STR2## wherein R.sup.2 is hydrogen, C.sub.1-6 -alkyl or C.sub.3-8 -cycloalkyl; Y is .dbd.O or .dbd.S or .dbd.NZ wherein Z is hydrogen, C.sub.1-6 -alkyl or --CN and R.sup.3 is selected from a group consisting of various structures have been found to exhibit high affinity for various receptor subtypes including the 5-HT.sub.2 receptor, the 5-HT.sub.1A receptor, the alpha.sub.1 receptor the dopamine receptor or a combination of these and may therefore be useful for treating CNS system, cardiovascular system and gastrointestinal disorders.
通式I的吡哌啉衍生物
其中R.sup.1代表取代苯基,1-或2-二氮杂萘基,氮杂萘基或二氮杂萘基;n为1、2、3或4;X为--O--或
其中R.sup.2为氢、C.sub.1-6-烷基或C.sub.3-8-环烷基;Y为.dbd.O、.dbd.S或.dbd.NZ,其中Z为氢、C.sub.1-6-烷基或--CN,R.sup.3从一组中选择,该组包括各种结构已被发现对各种受体亚型表现出高亲和力,包括5-HT.sub.2受体,5-HT.sub.1A受体,alpha.sub.1受体,多巴胺受体或这些受体的组合,因此可能对治疗中枢神经系统,心血管系统和胃肠道疾病有用。